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SUXAMETHONIUM -THE DEVELOPMENT OF A
MODERN DRUG FROM 1906 TO THE
PRESENT DAY*
by
HUW R. DORKINSt
1. INTRODUCTION
ON INITIALimpression, suxamethonium contrasts sharply with drugs such asdigitalis
or quinine in having a short, and fairly straightforward history. In fact, its emergence
as atherapeutically useful drug wassurprisinglylong and complex.
Suxamethonium (also known as succinylcholine, succinyldicholine) is a
neuromuscular blocking agent, commonly classed as a "depolarizing agent". It blocks
transmission of impulses from motor nerves to skeletal muscle by interacting with
receptors on the post-junctional membrane. These motor end-plate receptors nor-
mally combine with the transmitter molecule, acetylcholine, which is released from
the nerve terminal on the arrival of an action potential. Acetylcholine is synthesized
and stored in the nerve terminal. Its release results from nerve terminal depolariza-
tion, and depends on the entry of calcium ions. The transmitter molecules diffuse
across the neuromuscular junction and interact with motor end-plate receptors
causing adepolarization oftheend-plate, which isenough to initiateelectrical changes
leading to muscle contraction.
Suxamethonium is structurally similar enough to acetylcholine to cause a mem-
brane depolarization, and a muscle twitch, after which blockade sets in. Views of its
mechanism ofaction have changed as the understanding ofneuromuscular transmis-
sion has progressed.
2. CURARE-AN IMPORTANTCOMPETITIVENEUROMUSCULAR BLOCKING AGENT
The history of neuromuscular blocking agents starts with curare,1 a substance
which Koelle calls "a drug with a long and romantic history".2 Curare, a complex
* Dedicated to Professor W. Feldberg on the occasion ofhiseightieth birthday.
t Huw R. Dorkins, B.A., Wellcome Unit for the History of Medicine, 47 Banbury Road, Oxford OX2
6PE.
' The early literature on curare isvery large, e.g.: A. R. McIntyre, Curare: itshistory, nature, andclinical
use, University ofChicago Press, 1947; Philip Smith, Arrows ofmercy, Toronto, Doubleday, 1969; K. Bryn
Thomas, Curare - its history and usage, London, Pitman Medical, 1964; also in Lloyd G. Stevenson, The
meaning ofpoison, Lawrence, University of Kansas Press, 1959. A bibliography ofthe older literature is:
Instituto Brasiliero de Bibliografia e Documentacao, Curare - a bibliography, Rio de Janeiro, Conselho
Nacional de Pesquisas, 1957.
2George B. Koelle, 'Neuromuscular blocking agents', in Louis S. Goodman and Alfred Gilman (editors),
Thepharmacological basis oftherapeutics, 5th ed., New York, Macmillan, 1975, pp. 575-588.
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group of competitive neuromuscular blocking agents, has been used for centuries to
kill wild animals by tribes in South America, Borneo, and otheraboriginal cultures. It
is prepared as a crude extract of one or more of a variety of plants. In eastern
Amazonia, the principal sources are various species ofStrychnos, while the natives of
western Amazonia use Chondrodendron species. When a dart coated with curarehits
an animal, its skin is penetrated, the drug enters the circulation, and death due to
paralysis ofthe respiratory muscles promptly ensues. The advantage ofcurare is that
it is poorly absorbed through the gut wall ofpersons eating meat killed in this way -it
is thus a very specific poison.
Curare was known to western medicine in the nineteenth century. McIntyre,3 sur-
veying its clinical history, pointed out that its use in the treatment oftetanus was first
suggested by Sir Benjamin Collins Brodie (1783-1862)4 in a letter to Pierre Flourens
in 1811, also reporting his recent demonstration that curarized animals could be
resuscitated with artificial respiration.5 In 1858, Lewis Albert Sayre (1820-1900) first
used curare in human tetanus - unfortunately the patient, an Irish labourer in New
York, died.6 Over the next forty years, the use of curare in tetanus became
widespread, and epilepsy, hydrophobia, and chorea were similarly treated. Claude
Bernard (1813-1878) described the drug's neuromuscular blocking action in 1856,7
having worked with it since 1844.1
Modern clinical use of curare began in 1932, when Ranyard West9 employed
curare-based preparations in the treatment oftetanus and spastic disorders. However,
it was the introduction ofelectric shock therapy (ECT) for the treatment ofdepressive
illness that was to provide the main impetus for curare's widespread use. Indeed, the
entire ECT technique would have been abandoned had not an American psychiatrist,
Abram Elting Bennett (b. 1898), advanced the idea of using curare to block
neuromuscular transmission, thus preventing the disturbing occurrence of fractures
and dislocations due to massive contraction of skeletal muscles during treatment. '0"
I McIntyre, op. cit., note I above, pp. 182-208.
4Sir Benjamin Collins Brodie (the elder), the distinguished surgeon and physiologist, was the first
surgeon to be elected President of the Royal Society. Biographical sources include: Charles Hawkins
(editor), The works ofSir Benjamin Collins Brodie, with an autobiography, 3 vols., London, Longman
Green, 1865; Timothy Holmes, Sir Benjamin Collins Brodie, London, Fisher Unwin, 1898; W. R. LeFanu,
'Sir Benjamin Brodie FRS (1783-1862)', Notes Rec. R. Soc. Lond., 1964, 19: 42-52; [Obituary], Lancet,
1862, ii: 452-457, 482-483, 492, 521-522; K. Bryn Thomas, 'Benjamin Brodie: physiologist', Med. Hist.,
1964,8: 286-291.
5This letter, reported by Dieu in 1863, had been reproduced in Union med. Paris, 1859, 4: 98. (A. Dieu,
Histoiredu curare, Strasbourg, 1863.)
6 L. A. Sayre, 'Two cases of traumatic tetanus', N.Y. J. Med., 1858, 4: 250-253. Sayre was an eminent
American orthopaedic surgeon. His major contributions include the introduction of the plaster of Paris
jacket for treatment of tuberculosis of the spine. See Alfred R. Shandsjr., 'Lewis Albert Sayre, the first
professor oforthopaedic surgery in the U.S.', Curr. Pract. orthopaedic. Surg., 1969,4: 22-42.
7Claude Bernard, 'Analyse physiologique des propri6t6s des systemes musculaire et nerveux au moyen de
curare', Cr. hebd. Sianc. Acad. Sci., Paris, 1856, 43: 825-829.
8Thomas, op. cit., note 1 above, p. 62.
9 Ranyard West, 'Curare in man', Proc. R. Soc. Med., 1932, 25: 1107-1116.
10 Details of Bennett's life and work, including his work on curare, are given in his autobiography, Fifty
years inneurologyandpsychiatry, New York and London, Intercontinental Medical Book Corp., 1972.
11 A. E. Bennett, 'How "Indian arrow poison" curare became a usefuldrug', Archos. Neurobiol. (Madr.),
1965, 28: 606-620.
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Bennett and his colleagues at the Lincoln, Nebraska, Orthopedic Hospital first
produced temporary muscle relaxation in children with spastic paralysis. In 1940, they
successfully used curare in ECT for the first time, and it is due to the availability of
neuromuscular blocking agents that ECT is still in use today."2,3 This success led
Bennett to suggest to Lewis H. Wright of the American pharmaceutical company,
E. R. Squibb & Sons, that curare could usefully produce muscle relaxation during
general anaesthesia.14 The company had considerable experience in working with
curare: in 1938, Richard C. Gill, an American who had explored and worked in
Ecuador, brought back the largest amount of field-test curare so far gathered by an
outsider, and made this available to the Squibb research department.'5 In 1940, this
laboratory prepared a standardized curare extract called "Intocostrin"." Wright
discussed the matter with a Montreal anaesthesiologist, Harold R. Griffith (b. 1894),"7
who in 1942 carried out the first clinical trials of curare as a muscle relaxant on some
twenty-five patients.'8
A major problem with curare was difficulty of supply, for its availability limited the
extent of its investigation and exploitation. It was this, coupled with problems related
to the wide diversity seen in composition and neuromuscular blocking strength of the
various samples of curare collected, that stimulated work to find synthetic chemicals
with curariform action.
Over seventy years before the introduction of "Intocostrin", work had been done by
Alexander Crum Brown (1838-1922) and Thomas Richard Fraser (1841-1920) on the
pharmacological actions of quaternary salts. [A quaternary ammonium compound is
one in which all four hydrogen atoms of the ammonium ion (NH41 have been sub-
stituted by organic (carbon-containing) radicals.] Crum Brown and Fraser were
interested in the relationship between the chemical structure of a compound and its
biological activity.'9 They showed that a pharmacologically diverse group, the
12The continued use of ECT in the treatment of depressive illness is still problematic. The procedure is
currently being evaluated by clinical trials.
13 A. E. Bennett, 'Curare: a preventive of traumatic complications in convulsive shock therapy', Am. J.
Psychiat., 1941, 97: 1040-1060; idem, 'Preventing traumatic complications in convulsive shock therapy by
curare', J. Am. med. Ass., 1940, 114: 322-324.
14Idem, 'The history of the introduction of curare into medicine', Anesth. Analg. curr. Res., 1968, 47:
484-492.
'5 Bennett, op. cit., note 10 above.
160. Wintersteiner and J. D. Dutcher, 'Curare alkaloids from Chondrodendron tomentosum', Science,
1943,97:467-470.
17 Griffith subsequently became professor of anaesthesia at McGill University. An autobiographical
account is: H. R. Griffith, 'An anaesthetist's valediction', Can. Anaesth. Soc. J., 1967, 14: 373-381.
Is H. R. Griffith and G. E. Johnson, 'The use ofcurare in general anaesthesia', Anesthesiology, 1942, 3:
418-420.
"9The investigations of Crum Brown and Fraser form a link in a chain ofenquiry that continues to this
day. They were awarded the Makdougall Brisbane Prize of the Royal Society of Edinburgh (1866-68) for
this work. Neuromuscular blocking agents have featured repeatedly in studies of the relationship between
chemical constitution and biological activity and have been used in most of the theoretical models of
drug/receptor interaction. See: William F. Bynum, 'Chemical structure and pharmacological action: a
chapter in the history ofnineteenth-century molecular pharmacology', Bull. Hist. Med., 1970,44: 518-538;
John Parascandola, 'Structure-activity relationships - the early mirage', Pharm. Hist., 1971, 13: 3-10;
idem, 'The controversy over structure-activity relationships in the early twentieth century', ibid., 1974, 16:
54-63.
147H. R. Dorkins
alkaloids, if converted to quaternary salts, all lost their diversity of action, each
acquiring the neuromuscular blocking properties of curare.20 They were responsible
for producing the first synthetic curariform substances, "'readily obtained in a state of
perfect purity, and therefore, ofconstant strength".21,22,23
Crude curare is a very complex mixture ofmany different alkaloids. The next step
in the development ofneuromuscular blocking agents was the attempt to extract and
purify individual components of curare, with a view to determining their chemical
structure. One such component is d-tubocurarine. The pure alkaloid was isolated and
extracted from a small bush plant, Chondrodendron tomentosum, a known source of
curare, by Harold King (1887-1956), an organic chemist working at the National
Institute for Medical Research (NIMR) in Hampstead. It was a very difficult task,
involving a complex method of extraction, using first ether and then chloroform.
Nonetheless, King was able in 1935 to publish the chemical structure he had deter-
mined for d-tubocurarine.24 The alkaloid was called "tubocurarine" because it was a
component in a type ofcrude curare classified by Boehm as tube curare - a reference
to the bamboo tubes used by South American Indians to store this type ofcurare.25
The structure that King had worked out for d-tubocurarine was that of a large,
relatively rigid molecule, containing two quaternary ammonium groups, at opposite
ends of the molecule (Fig. la). King's chemical characterization of d-tubocurarine
marked the start of a period of rapid advance in neuromuscular pharnmacology, and
enabled synthetic chemists and pharmacologists to start work on making simpler
molecules with properties similar to those of curare. Some years later, Harington
(director ofthe NIMR) commented, "It was however the work of King on the curare
alkaloids which I think really opened up the way to the systematic pharmacological
work that has proved so profitable. King's research on curare was a masterly series of
investigations extending over many years, and leading from the isolation of d-
tubocurarine in the pure state to the determination of the constitution of this
alkaloid" 26,27
20Thomas, op. cit., note 1 above, p. 77.
21 A. Crum Brown and T. R. Fraser, 'On the connection between chemical constitution and physiological
action. Part I. On the physiological action of the salts of the ammonium bases derived from strychnia,
brucia, thebaia, codeia, morphia, and nicotia', Trans. R. Soc. Edinb., 1868, 25: 151-203.
22Crum Brown and Fraser reported further work in 'On the connection between chemical constitution
and physiological action. Part II. On the physiological action ofthe ammonium bases derived from atropia
and conia', ibid., 1869, 25: 693-739.
23 Crum Brown trained in medicine at Edinburgh University, and subsequently became interested in
organic chemistry. Biographical accounts include: [Obituary], J. chem. Soc., 1923, 123: 3422-3431; D. C.
Goodman, 'Alexander Crum Brown', in C. C. Gillispie (editor), Dictionary ofscientific biography, vol. 2,
New York, Charles Scribner's Sons, 1970, pp. 514-516; D. F. Larder, 'Alexander Crum Brown and his
doctoral thesis of 1861', Ambix, 1967, 14: 112-132.
Fraser, also a medical graduate ofEdinburgh, was professor ofmateria medica there from 1877 to 1918.
He was elected FRS in 1877, and knighted in 1902. See: [Obituary], Br. med. J., 1920, i: 100-101;
[Obituary], Proc. R. Soc. Lond., 1921, 92B: xi-xvii.
24 H. King, 'Curare alkaloids. Part I -tubocurarine',J. chem. Soc., 1935, 1381-1389.
25 It has since become clear that the method of storage used for curare is not related to its chemical
structure -any ofthevarious curare alkaloidsmight be present in any type ofcontainer.
26 Charles Harington, 'Opening remarks', in M. Harington (editor), Hypotensivedrugs:proceedingsofa
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Figure 1.
(a) King's initial structure ford-tubocurarine(chloride). Two quaternary nitrogen atoms are present.
(b) General chemical formula for members of the methonium series. The structure (Polymethylene bis-
trimethyl ammonium) can incorporate a variable number (n.) of methylene (- CH2 -) groups, allowing
varying degrees ofseparation ofthetwo positively charged, quaternary nitrogen atoms.
(c) Revised structure for d-tubocurarine (chloride). The positions ofthe hydroxyl groups were modified by
King, Everett etal.," who showed that one ofthenitrogen atoms(arrow) was not quaternary.
symposium on hypotensive drugs and the control ofvascular tone in hypertension, London and New York,
Pergamon Press, 1956, pp. 1-3.
27 Harold King, an outstanding organic chemist, was made FRS in 1933. The most informative obituary
is: C. Harington, 'Harold King, 1887-1956', Biogr. Mem. Fellows R. Soc. Lond., 1956, 2: 157-171. Other
obituaries include: Nature, Lond, 1956, 177: 604-605; Br. med.J., 1956, i: 521-522, 578.
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During the 1930s, the NIMR was a world centre of pharmacological research.
Henry Hallett Dale (1875-1968) had gone there in 1914, and from 1928 to 1942 was
Director ofthe Institute. However, he maintained his active research interests and his
laboratory attracted many distinguished physiologists and pharmacologists, including
Wilhelm Feldberg (b. 1900), J. H. Gaddum (1900-1965), Marthe Vogt (b. 1903), and
G. L. Brown (1903-1971). There can be little doubt that King's interest in the curare
alkaloids was stimulated by the work of Dale and his colleagues on the chemical
transmission of nerve impulses at the neuromuscular junction. The years 1933-36
were ones of outstanding progress in Dale's group, with some twenty-four papers
published in the Journal ofPhysiology on the transmitter role ofacetylcholine at the
neuromuscular junction, autonomic ganglia, and a variety of other sites.28 Clearly,
knowledge ofthe structure ofa substance which blocked neuromuscular transmission
was of considerable importance. However, King's interest in alkaloids began much
earlier, before he joined the NIMR. In 1912, he worked at the Wellcome
Physiological Laboratories, then under Dale's direction. King then moved to the
Wellcome Chemical Laboratories at Dartford. There, in the laboratory ofFrank Lee
Pyman, his studies on alkaloids began with the isolation of1-hyoscine, and the resolu-
tion of hyoscine and its components, oscine and tropic acid. He joined the Medical
Research Council shortly after the end ofWorld War I, which brought him back into
contact with Dale.29 He remained with the MRC for thirty-one years, until his retire-
ment in 1950. As we shall see, the Hampstead laboratory produced one ofthe major
contributions to the methonium compounds over adecade later.
3. THE METHONIUM COMPOUNDS
Progress on synthetic curare substitutes was delayed by the outbreak ofWorld War
II four years after the publication of King's first paper on curare alkaloids. However,
by the late 1940s, interesting compounds began to appear. Many workers tried to syn-
thesize structures related to, but less complicated than d-tubocurarine,30 and a few
groups chose to make molecules containing two quaternary nitrogen atoms. In 1948,
two groups of British workers, Barlow and Ing3' and Paton and Zaimis,32 reported
work on a family ofcompounds characterized by such a bis-quaternary structure(Fig.
1b).
Barlow and Ing based their work on the imitation ofthe bis-quaternary structure of
28 A fascinating and authoritative eyewitness account of this period can be found in: Wilhelm Feldberg,
'The early history of synaptic and neuromuscular transmission by acetylcholine: reminiscences of an eye
witness', in The pursuit ofnature. Informal essays on the history ofphysiology, Cambridge University
Press, 1977, pp. 65-83.
29 The influence of Dale on King's work is assessed in Harington, op. cit., note 26 above. King appears to
have written little other than his scientific papers - no evidence about the origin of his interests could be
found in the NIMR archives.
3 Koelle, op. cit., note 2 above, p. 575.
31 R. B. Barlow, and H. R. Ing, 'Curare-like action ofpolymethylene bis-quaternary ammonium salts',
Nature, Lond., 1948, 161: 718.
32 W. D. M. Paton and E. J. Zaimis, 'Curare-like action of polymethylene bis-quaternary ammonium
salts', ibid., 718-719.
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curare.3334 William D. M. Paton (b. 1917) and Eleanor Zaimis (b. 1915) were at
NIMR, Hampstead; not, in fact, studying neuromuscular blocking compounds, but
drugs that cause histamine release. Paton's observation of slight, but definite,
respiratory arrest with a member of another set of histamine releasing dibasic
compounds35 alerted him to a pharmacological action at the neuromuscular junction,
and on studying the diquaternary compound of the formula shown in Fig. lb, where
n =8, the principal action seen was one of respiratory arrest. In a subsequent paper,
Paton and Zaimis said, "Our attention was drawn to the [methonium] series during a
test of the power of the octamethylene compound to liberate histamine".36 They
therefore discovered the series as a result ofcareful observation in experimental work:
unlike Barlow and Ing, they did not approach the problem from a theoretical basis
starting with the structure ofd-tubocurarine.
Why did Barlow and Ing become interested in these diquaternary compounds? The
answer can be found with Ing's long-standing interest in the relationship between
chemical structure and biological activity. While at the Pharmacology Department of
University College London, with Winifred Wright during the late 1920s and early
1930s, Ing had worked on the curariform action of onium salts, such as those of
tetramethylammonium ([CH3]4N+), tetramethylphosphonium ([CH3]4P ), and
trimethylsulphonium ([CH3]3 S+).37 By the 1940s, he had come to the view that the
powerful curare-like activity of tubocurarine might be due to the presence of two
quaternary groups at some optimal distance apart in the molecule. It was for this
reason that he set out to imitate the structure ofd-tubocurarine.38
These compounds became known as the methonium series, and one of them,
decamethonium, was found to be a valuable depolarizing agent. The series also
included hexamethonium, a ganglion blocking drug which became important in the
treatment of hypertension.39 The synthesis of the methonium compounds, and the
33 R. B. Barlow, 'The synthesis and pharmacological properties of bis-onium salts', B.Sc. thesis, Oxford
University, 1949.
Richard Barlow (b. 1925) was a research student at Oxford working for the degree of B.Sc., with Harry
Raymond Ing (1899-1974) as his supervisor.
34 Ing, by training an organic chemist, was an eminent "chemical pharmacologist". He became FRS in
1951. See H. 0. Schild and F. L. Rose, 'Harry Raymond Ing, 1899-1974', Biogr. Mem. Fellows R. Soc.
Lond., 1976, 22: 239-255.
31 W. D. M. Paton, personal communication, 1978.
36 W. D. M. Paton and E. J. Zaimis, 'The pharmacological actions of polymethylene bis-
trimethylammonium salts', Br. J. Pharmac. Chemother., 1949, 4: 381-400.
37 Accounts ofthis work can be found in: H. R. Ing and W. M. Wright, 'The curariform action ofquater-
nary ammonium salts', Proc. R. Soc. Lond., 1931, 109B: 337-353; idem, 'Further studies on the phar-
macological properties of onium salts', ibid., 1933, 114B: 48-63; H. R. Ing, 'The curariform action of
onium salts', Physiol. Rev., 1936, 16: 527-544.
"I Ing was a friend of King, and well aware of his work. In his lectures on chemical pharmacology at
Oxford, Ing used to show his students how, in both decamethonium and d-tubocurarine, ten atoms
separated the two quaternary nitrogen atoms, suggesting the existence of an optimal separation for
neuromuscular block. (Barlow, personal communication, 1979.)
39 Hexamethonium has now been superseded by more modern hypotensive drugs. However, its value
should not be underestimated, as it proved to be ofmajor importance in the treatment ofdangerously high
blood pressure, at a time when few alternatives were available. See, M. Perutz, 'Health and the Medical
Research Council', Nature, Lond., 1972, 235: 191-192.
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demonstration oftheir clinical potential,40 led to increased interest in this field, and it
was not surprising that, in 1949, the curariform action of suxamethonium was
described by three independent groups in Italy, Great Britain, and the United States.
The Italian group, which first described the powerful neuromuscular blocking
properties of suxamethonium, was led by Daniel Bovet (b. 1907).41 They began work
on synthetic curare substitutes in 1946, perhaps atypically, by studying molecules
chemically similar to d-tubocurarine, going on to work with simpler compounds. In
1947, they described a new synthetic agent with a powerful competitive
neuromuscular blocking action, which acquired the name Gallamine. The British
group included James Walker (b. 1908), Gladwyn Albert Hurst Buttle (b. 1899), and
Eleanor Zaimis. Walker was an organic chemist working at Hampstead; Buttle and
Zaimis were pharmacologists. In fact, Zaimis had considerable chemical experience
as well, with degrees in both chemistry and medicine. During the course ofthis work,
she had synthesized many methonium compounds, some of them for the first time.
The American group, based at the Wellcome Research Laboratories in New York
State, comprised an organic chemist Arthur P. Phillips, and Julio C. Castillo (b. 1905)
and Edwin J. de Beer (1902-1959),42 who studied the pharmacology of
suxamethonium. Both Paton43 and Zaimis44 believe that so much effort was put into
the study of suxamethonium because of the success of decamethonium, a view con-
firmed by the original papers. The success ofdecamethonium was seen as a function of
the distance between the two nitrogen atoms [i.e. ten carbon atoms]. Suxamethonium
was considered a strong candidate because, as in decamethonium, the two nitrogen
atoms were ten atoms apart (Fig. 2).
The other major reason for interest in suxamethonium was its similarity to two ace-
tylcholine molecules laid end to end. In the British group, F. C. MacIntosh (also at
Hampstead) pointed this out, and James Walker went on to make the compound.
Additional evidence to support this view came from the American group; one oftheir
publications explicitly called suxamethonium "diacetylcholine".45
40The demonstration ofthe clinical potential ofdecamethonium was under way when the first reports on
the synthesis and pharmacological properties of suxamethonium emerged. For an early demonstration of
the clinical usefulness ofdecamethonium, see G. Organe, W. D. M. Paton and E. J. Zaimis, 'Preliminary
trials ofbistrimethylammonium decane and pentanediiodide(CIO and C5) in man', Lancet, 1949, i: 21.
41 Bovet made many contributions to pharmacology, for which was awarded the Nobel Prize in 1957 (see
Daniel Bovet, 'The relationships between isomerism and competitive phenomena in the field ofdrugtherapy
of the autonomic nervous system and that of the neuromuscular transmission', in Nobel Lectures in
Physiology or Medicine 1942-1962, Amsterdam, Elsevier, 1964, pp. 552-578). He also synthesized
antihistamines. Among the best accounts of Bovet's work are: 'Nobel laureates: Prof. Daniel Bovet',
Nature, Lond., 1957, 180: 951; and Theodore L. Sourkes, Nobelprize winners in medicine orphysiology
1901-1965, (revision of an earlier work by Lloyd G. Stevenson), London and New York, Abelard-
Schuman, 1966, pp. 342-351.
42 [Obituary], 'Edwin John de Beer', New York Times, 28 October 1959, p. 37.
43 Paton, op. cit., note 35 above.
44 E. J. Zaimis, personal communication, 1978.
4 J. C. Castillo and E. J. de Beer, 'The neuromuscular blocking action of succinylcholine (diace-
tylcholine)',J. Pharmac. exp. Ther., 1950, 99: 458-464.
Barlow, in op. cit., note 33 above, pointed out the structural similarity of two acetylcholine molecules
with one molecule of decamethoniumn. Recently, F. C. MacIntosh claimed that the idea of "diace-
tylcholine" and its synthesis by Walker occurred at Hampstead some time before it was made and tested by
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Figure 2.
(a) Decamethonium.
(b) Suxamethonium.
(c) Acetylcholine (ACh). This is the transmitter molecule at the neuromuscularjunction in man. The fact
that suxamethonium is diacetylcholine is shown on comparison of the chemical structure of ACh with
that ofsuxamethonium (b). Suxamethonium is clearly two ACh molecules stuck end to end at the point
shown by the arrows.
In 1949, the Italian group published their main paper on suxamethonium," whilst
in the same year, Buttle and Zaimis47 and Phillips4" presented papers on its phar-
any other worker. He went on to state that he tested thedrug, and that its very short duration ofaction led
him to reject it. He did not realize that a short-acting drug has a number ofpractical advantages compared
with a longer-acting blocking agent; forexample, it facilitates the precise minute-to-minute control ofthe
depth of neuromuscular block. This was confirmed by Walker. F. C. MacIntosh, 'The Sarrazin Lecture
1979: the age of bioassay, or my early stumbles on the trail of histamine and acetylcholine', Canad.
Physiol., 1979, 10: 65-79.
" D. Bovet, F. Bovet-Nitti, S. Guarino and V. G. Longo, 'Proprieta farmacodinamiche di alcuni derivati
della succinilcoline dotati di azione curarica. Esteri di trialchiletanolammonio di acidi bicarbossilici
alifatici', Rc. Ist. sup. Sanita, Roma, 1949, 12: 106-137.
47 G. A. H. Buttle and E. J. Zaimis, 'The action ofdecamethonium iodide in birds', J. Pharm. Pharmac.,
1949, 1:991-992.
"8 Arthur P. Phillips, 'Synthetic curare substitutes from aliphatic dicarboxylic acid aminoethyl esters', J.
Am. chem. Soc., 1949, 71: 3264. In the same year, the American group published their work on the
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macology and synthetic chemistry respectively. The following year saw Walker's
paper on suxamethonium synthesis,49 and the pharmacological account of Castillo
and de Beer.50 Thus, several papers on the methonium compounds emerged quickly
from a few laboratories around the world.
To what extent were these three groups truly independent? All three clearly knew of
each other's work, both the American and the British workers specifically citing
Bovet's work in their publications. The precise links are more difficult to ascertain.
There were close contacts between Bovet and two British laboratories, the Phar-
macology Department at Oxford5' and the London School of Pharmacy (the home of
Buttle and, briefly at this period, Zaimis).52'53 However, there is nothing to suggest
that the three reports on the chemical synthesis of suxamethonium are anything less
than accounts ofquite independent work.
4. EARLIER WORK ON SUXAMETHONIUM
This account so far has portrayed the discovery of suxamethonium as a fairly
logical process, starting with King's work on d-tubocurarine and moving through
work on simple methonium compounds, culminating in the synthesis of
suxamethonium itself. But, scientific research rarely progresses so tidily; there is more
to the history of suxamethonium than is immediately evident. Bovet's synthesis of it
was not the first; it is clear from his 1949 paper54 that he knew of the work of Reid
Hunt55 and Rene de M. Taveau, two workers who prepared succinylcholine
(suxamethonium) as early as 1906. In a paper published in that year, (i.e., fifteen years
before Otto Loewi's classic experiments on chemical transmission and some thirty
years before the demonstration ofthe role ofacetylcholine in the neuromuscularjunc-
structurally similar decamethonium: J. C. Castillo, A. P. Phillips and E. J. de Beer, 'The curariform action
ofdecamethylene - 1, 10- bis-trimethylammonium bromide',J. Pharmac. exp. Ther., 1949,97:150-156.
49J. Walker, 'Some new curarizing agents', J. chem. Soc., 1950, 193-197.
'0Castillo and de Beer, op. cit., note 45 above.
51 Bovet's group collaborated with the Oxford Pharmacology Department in the late 1940s. Edith
B0lbring, a member of the Oxford department, went to Bovet's group for some months early in 1948, and
this was followed by a visit to Oxford by Mlle. France Depierre from Bovet's laboratory at the Institut
Pasteur, Paris. While in Oxford, Depierre worked with Bullbring on analogues of the competitive
neuromuscular blocking agent Gallamine. This work was reported in: Edith Biulbring and France Depierre,
'The action ofsynthetic curarizing compounds on skeletal muscle and sympathetic ganglia both normal and
denervated', Br. J. Pharmac. Chemother., 1949, 4: 22-28. No work was done on succinylcholine during this
visit. (E. Bulbring, personal communication, 1981.)
52 G. A. H. Buttle was (and remains) a close friend of Bovet. In the 1930s, Buttle - then working at the
Wellcome Laboratories - travelled to Paris every weekend to follow Bovet's progress. After World War II,
Buttle was appointed to the Wellcome Chair of Pharmacology at the London School of Pharmacy, and con-
tinued to visit Bovet regularly while he was working on neuromuscular blocking agents. (G. A. H. Buttle,
personal communication, 1981.) Autobiographical information may be found in: G. A. H. Buttle, 'A full
circle', Trendspharmacol. Sci., 1980, 1: 443-445.
53 Professor Zaimis described the late forties as an intensely exciting time: a period of rapid advance in
neuromuscular pharmacology. Zaimis, op. cit., note 44 above.
54 Bovet et al., op. cit., note 46 above.
" Reid Hunt (1870-1948) became chief of the Division of Pharmacology in the U.S. Public Health
Service in 1906, and Professor of Pharmacology at Harvard from 1913 to 1926. See [Obituary], New York
Times, 11 March 1948, p. 27; G. P. Grabfield, [obituary], Science, N. Y., 1948, 108: 127.
154Suxamethonium
tion by Dale's group), they made telling comments. Writing of the physiological
effects ofcholine and its derivatives, Hunt noted:
I have recently taken this subject up again in conjunction with Mr. Taveau and I desire today to report
briefly some of our results. We have studied 19 such compounds, all but two of which, (the acetyl and
benzoyl compounds) are new. Acetyl-cholin: Acetyl-cholin ... is a substance of extraordinary
physiological activity. In fact, I think it is safe to say that as regards its effect upon the circulation, it is
the most powerful substance known. Wehave notdetermined the cause ofthe fall ofblood pressure from
acetyl-cholin, but from the fact that it can be prevented entirely by atropine, I am inclined to think that it
is due to an effect upon the terminations ofthevagus in theheart.36
Hunt, when describing his methods, mentioned that his results were obtained on
thoroughly anaesthetized and curarized animals. Curare was used "so as to avoid any
interference from effects upon the respiration". He then concluded: "Succinyl-cholin
... was the only compound of the aliphatic dibasic acids studied, its physiological
action is similar to that of the valeryl compound ... causing a marked slowing ofthe
heart". By curarizing his animals, Hunt had missed the neuromuscular blocking
properties of suxamethonium. This then went undiscovered for over forty years. A
further, and much more detailed report was published in 1911.57 Here, Hunt and
Taveau were concerned with theeffects ofcholine and someeighty ofits derivatives on
the circulation and blood pressure, i.e., effects at autonomic ganglia and at a different
type of receptor (muscarinic) site for acetylcholine, rather than with the effects at the
nicotinic receptors of the neuromuscular junction. Succinylcholine was also
mentioned in this report, but again no neuromuscular blocking action was described.
One passage in this paper described an experiment to study theeffects ofacetylcholine
on a non-curarized animal. On injecting acetylcholine, Hunt observed an atypical
biphasic response in blood pressure. He also saw "slight muscular movements", and
ascribed the cause ofthe changes in blood pressure to this muscle activity.58
What was the origin of Hunt's interest in choline and its derivatives? He had for
some years been investigating the effects of extracts of the adrenal gland on blood
pressure. It was well known that adrenalin raised the blood pressure, but Hunt had
established that other extracts of the same gland could depress it. He had identified
one ofthese as choline, but had also shown that this was not theonly hypotensive con-
stituent ofthese extracts. This caused him to begin the systematic study ofcholine and
its derivatives, during which he synthesized suxamethonium.
However, the work of Hunt and Taveau did not represent the last appearance of
succinylcholine before 1949. Some ten years after the publication of their second
paper, Le Heux in Germany worked on the effect ofsuccinylcholine on in vitro rabbit
56 Reid Hunt add R. de M. Taveau, 'On the physiological action of certain cholin derivatives and new
methods fordetectingcholin', Br. med.J., 1906, ii: 1788-1791.
57Idem, 'The effects of a number of derivatives of choline and analogous compounds on the blood-
pressure', Bull. hyg. Lab., Wash., 1911, 73.
58 Sadly, Hunt did not continue to study acetylcholine, nor did he realize that movement of the muscle
was caused by acetylcholine acting directly on it. Hunt and Taveau were not the only workers before Dale's
group to deal with the action ofacetylcholine on muscle; an example is the work ofOtto Riesser, 'Beitrage
zur Kenntnis des Azetylcholins', Arch. exp. Path. Pharmakol., 1931, 161: 34.
An excellent guide to the literature of the early period of transmitter work is: J. H. Gaddum,
Gefasserweiternde Stoffe der Gewebe, Leipzig, Thieme, 1936. Translated by W. Feldberg, it appeared only
in German. (H. Blaschko, personal communication, 1979.)
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intestine, in connexion with studies on choline and its derivatives. He reported it to
have only a relatively slight effect on peristalsis.5960 In 1941, Glick synthesized
suxamethonium (for what he thought was the first time) and showed its susceptibility
to hydrolysis.61
Thus it is clear that the synthesis and description ofthe pharmacological actions of
suxamethonium had been a series of "near misses" until Bovet finally observed
neuromuscular block in 1949. Why did Bovet find an effect that had eluded three other
groups? Part ofthe answer is that he was the first to produce experimental conditions
conducive to the appearance of neuromuscular blocking action, e.g., the use of
animals not given curare which would mask this action. It is tempting to suggest that
Bovet was the first to succeed because, unlike his predecessors, he knew what he was
looking for. Experience with decamethonium had shown neuromuscular blocking
action to be associated with a polymethylene bistrimethylammonium structure (the
structure ofthe methonium series), and it now seems natural enough to move from the
ten carbon atom separation ofthe two nitrogen atoms in decamethonium to the same
separation in suxamethonium. One other factor contributed to Bovet's success: the
fact that he worked many years after Dale, when thetransmitter role ofacetylcholine
was well established.
Some twenty years after Bovet's paper, the theoretical basis ofthe synthesis ofthe
methonium compounds was to be questioned. As mentioned above, the starting-point
for Bovet's work was the elucidation of the structure of d-tubocurarine by King in
1935. The structure was subsequently revised in 193962 and 1948.63 These revisions
were not important in terms of their implications for the development of
suxamethonium, in that no structural modifications were suggested at either of the
two nitrogen atoms. Barlow and Ing synthesized the methonium compounds with the
double quaternary configuration of d-tubocurarine in mind. Ironically, in 1970,
Everett et al." reported that d-tubocurarine does not contain two quaternary nitrogen
atoms (Fig. lc).65'66
59 S. Thesleff, 'Succinylcholine Iodide - studies on its pharmacological properties and clinical use', Acta
physiol. scand., 1952. 27, Suppi. 99.
60J. W. Le Heux, 'Cholin als Hormon der Darmbewegung. III Mitteilung; Die Beteiligung des Cholins
an der Wirkung verschiedener organischer Sauren aufden Darm', Pflugers Arch. Ges. Physiol., 1921, 190:
280-300.
61 David Glick, 'Some additional observations on the specificity ofcholinesterase', J. biol. Chem., 1941,
137: 357-362.
62 Harold King, 'Curare alkaloids. Part IV - bebeerine and tubocurarine, orientation ofphenolicgroups',
J. chem. Soc., 1939, 1157-1164.
63Idem, 'Curare alkaloids. Part VII -constitution ofdextro-tubocurarine chloride', ibid., 1948, 265-266.
" A. J. Everett, L. A. Lowe and S. Wilkinson, 'Revision ofthe structures of(+) - tubocurarine chloride
and (+) -chondrocurine', Chem. Commun., 1970, 1020-1021.
6" The revised structure was confirmed in 1973, in a thorough crystallographic analysis: P. W. Codding
and M. N. G. James, 'The crystal and molecular structure of a potent neuromuscular blocking agent: d-
tubocurarine dichloride pentahydrate', Acta Crystallogr., 1973, 298: 935-942.
"The reason for the error in King's structure for d-tubocurarine is well explained by Maclagan. In much
of his chemical work, King used the dimethyl ether ofd-tubocurarine. There is now little doubt that the
chemical reaction that yields the dimethyl ether also causes the replacement of a hydrogen atom at one
nitrogen atom by a methyl group, i.e., the dimethyl ether is a diquaternary nitrogen compound. (Jennifer
Maclagan, 'Competitive neuromuscular blocking drugs', in Eleanor Zaimis (editor), Handbook ofexperi-
mental pharmacology, vol. 42: Neuromuscular junction, Berlin, Heidelberg, and New York, Springer,
1976, pp. 421-486.)
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A group of very useful drugs was thus discovered on the premise that d-
tubocurarine was a diquaternary salt, an assumption later found to be inaccurate.67
5. CLINICAL APPLICATION
Following the synthesis ofsuxamethonium in the late 1940s, the drug was clinically
tested in the early 1950s. The areas in which it would be useful were to some extent
already known, because of the earlier careful evaluation of decamethonium
(1949-1953). Suxamethonium, a neuromuscular blocking agent, would be useful in
producing a profound muscle relaxation. As Dripps68 points out, "Muscle relaxation
of varying degrees is needed in many surgical procedures ... relaxation of the jaw
muscles assists intubation of the trachea, and the reduction of a dislocated shoulder
can be facilitated by the use of a muscle relaxant". Muscle relaxation is also very
helpful in abdominal surgery. The other important application ofsuxamethonium was
also easily predicted: as ashort-acting curaresubstitute to protect patients undergoing
ECT.
Paton69 identifies two figures with key roles in advancing the use ofsuxamethonium:
in America, an anaesthesiologist, Francis Foldes; and in Sweden, Stephen Thesleff.
Feldman70 notes the contributions of Brucke and his associates and Mayrhofer and
Hassfurther in Austria;71 and Scurr7 and Boume and his colleagues in the U.K., in
introducing suxamethonium intheircountries.
67The structure-activity relation of the d-tubocurarine molecule has remained a topic for detailed
scrutiny. It has been pointed out that although the molecule is not diquaternary, it is likely to have two
positively charged centres at normal physiological pH, because the tertiary nitrogen atom will be
protonated. See W. C. Bowman and M. J. Rand, Textbook ofpharmacology, 2nd ed., Oxford, Blackwell
Scientific, 1980, ch. 17, p. 34.
The notion of the existence of an optimal distance of separation of the two nitrogen atoms for
neuromuscular blocking activity has now been called into question. This idea was important as the basis of
the work of Ing and others. However, it has been pointed out that while the distance between the two
quaternary ammonium groups in d-tubocurarine is 1.4-1.5 nm, pancuronium, a competitive blocking agent
four to five times more potent,has a separation of 1.0-1.1 nm, while the new blocking drug fazadinium (also
called AH 8165) has 0.7 nm between its two quaternary ammonium groups. Furthermore, the role of the
quaternary ammonium groups is not clear, the neuromuscular blocking activity of "-erythroidine and
dihydro-frerythroidine is abolished when the tertiary nitrogen atoms are made quaternary. See: S. A.
Feldman, 'Neuromuscular blocking drugs', in H. C. Churchill-Davidson (editor), A practice ofanaesthesia,
4th ed., London, Lloyd-Luke, 1978, p. 865; Palmer Taylor, 'Neuromuscular blocking agents', in Alfred
Goodman Gilman et al,, (editors), The pharmacological basis of therapeutics, 6th ed., New York,
Macmillan, 1980, pp. 220-234.
Finally, it would appear that d-tubocurarine does not have a purely competitive moie ofaction. A very
thorough recent analysis suggests that under some circumstances, d-tubocurarine blocks the flow of ions
that causes the depolarization of the muscle end plate, rather than simply competing with acetylcholine
for receptor sites. See D. Colquhoun, 'Competitive block and ion channel block as mechanisms of
antagonist action in the skeletal muscle end-plate', in G. Pepeu et al. (editors), Receptors for
neurotransmitters and peptide hormones. (Advances in biochemical psychopharmacology, vol. 21), New
York, Raven Press, 1980, pp. 67-80.
68 Robert D. Dripps, 'The clinician looks at neuromuscular blocking drugs', in Zaimis, op. cit., note 66
above, pp. 583-592.
69 Paton, op. cit., note 35 above.
70 Feldman, op. cit., note 67 above.
710. Mayrhofer and M. Hassfurther, 'Kurzwirkende Muskelerschlaffungsmittel; Selbstversuche und
klinische Erprobung am narkotisierten Menschen', Wien. klin. Wschr., 1951, 63: 885-889.
72C. F. Scurr, 'A relaxant ofvery briefaction', Br. med. J., 1951, ii: 831-832.
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The years 1950-53 witnessed intense activity; the drug was selectively tried out on a
few patients, generally found to be successful, and papers by practising clinicians in
clinical journals around the world brought it to the attention of their colleagues.73 74 75
Many of these papers referred to suxamethonium by its other name,
succinyldicholine. The latter name more accurately reflects its composition as an ester
of two choline moieties with the dicarboxylic acid, succinic acid. It was known before
the start of clinical trials that suxamethonium was a short-acting drug. In 1941,
Glick76 discovered that it was very rapidly hydrolysed by non-specific "esterase"
enzymes found in the blood plasma." This was subsequently confirmed by Bovet-Nitti
in 1949.71 Ten years later, it was shown that the product of succinylcholine hydrolysis
was succinylmonocholine.79 This is an intermediate, which is subsequently hydrolysed
to succinate and choline. Succinylmonocholine was considered by Bovet to be phar-
macologically inactive80 but was later shown to have blocking properties similar to
those of suxamethonium but with much lower potency.81 Choline also has some
neuromuscular blocking activity, but at physiological concentrations this is unlikely to
have a significant effect. Paton82 considers suxamethonium's susceptibility to
hydrolysis to be important in its development as a drug, yet he also points out that
brevity of action is one possible explanation why suxamethonium did not replace
decamethonium as the muscle relaxant ofchoice earlier, for at that time the "target"
neuromuscular blocking agent was a long-acting drug.
The initial clinical trials went very well,83,84,85,86and in March 1952, von Dardel and
Thesleff wrote: "Muscular relaxation was found to be satisfactory in every case. No
cumulative effect or tachyphylaxis was observed. No complications or toxic actions
were encountered, either during anaesthesia or post-operatively, that could be
73 H. Brucke, K. H. Ginzel, H. Klupp, F. Pfaffenschlager and G. Werner, 'Bischolinester von Dicar-
bonsauren als Muskelrelaxanter in der Narkose', Wien. klin. Wschr., 1951,63: 464-466.
74 S. Thesleff, 'Pharmacological and clinical tests with L.T.I (0.0-succinylcholine iodide)', Nord. Med.,
1951,46: 1045.
75 0. von Dardel and S. Thesleff, 'Clinical results with succinylcholine iodide, a new muscle relaxant',
ibid., 1951, 46: 1308-1311.
76 It is clear that Glick's main interest was in the enzymes responsible for the hydrolysis ofcholine esters.
Although he synthesized suxamethonium, this was only used as a "biochemical probe" to study the
cholinesterases.
77 Glick, op. cit., note 61 above.
7' F. Bovet-Nitti, 'Degradazione di alcune sostanze curanzzanti per azione di colinesterasi', Re. Ist.
sup. Sanita. Roma, 1949, 12: 138-157.
79 V. P. Whittaker and S. Wijesundera, 'The hydrolysis ofsuccinyldicholine by cholinesterase', Biochem.
J., 1952, 52:475-479.
80 D. Bovet, F. Bovet-Nitti, S. Guarino, V. G. Longo and R. Fusco, 'Recherches sur les poisons
curarisants de synthese; succinylcholine et derives aliphatiques', Archs. int. Pharmacodyn. Ther., 1951, 88:
1-50.
81 H. Lehmann and E. Silk, 'Succinylmonocholine', Br. med. J., 1953, i: 767-768.
82 Paton, op. cit., note 35 above. See also note45 above.
"I Brucke, op. cit., note 73 above.
84 Von Dardel and Thesleff, op. cit., note 75 above.
8 0. von Dardel and S. Thesleff, Communication to the twenty-sixth International Congress on
Anaesthesiology, London, September 1951.
86 G. Holmberg and S. Thesleff, 'Succinylcholine as a muscle relaxant in electroshock therapy', Nord.
Med., 1951, 46: 1567-1569.
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ascribed to the use of succinylcholine iodide as a muscular relaxant".87 Similarly, in
June 1952, Foldes noted: "Its use is not accompanied by unwanted side effects and the
incidence of post-operative complications after its use is low. On the basis of limited
experience, succinylcholine seems to be the muscle relaxant of choice of all similar
agents so far investigated."88
6. SUXAMETHONIUM AND THE DEVELOPMENT OF PHARMACOGENETICS
Suxamethonium would have been exceptional indeed if it had had no major side-
effects. When individual sensitivity to a drug varies by a factor of at least three, this is
not surprising. Before publication, Foldes included an addendum to his paper of June
1952, drawing attention to reports of several instances of respiratory depression
following the use ofsuxamethonium. These reports 19 9019'92were the first indications of
its associated side-effects,93 which, typically, came to light only after the start of
relatively large-scale trials. These reports were atypical in marking the start of a new
phase in the history of suxamethonium: its contribution to the then very young and
developing science ofpharmacogenetics.
The term "pharmacogenetics" - the study ofthe genetic component in the response
of an individual to a drug - was not coined until 1957.94 The contribution of
suxamethonium to the development of pharmacogenetics illustrates how, in the
attempts to unravel a problem, the nature of the scientific questions asked inevitably
limits the usefulness ofthe answers in its solution.
Probably the best early review of the difficulties with the clinical application of
suxamethonium is that by Bourne et al.95 This paper, and one by Evans et al.96 in the
same issue of the Lancet, put into perspective the problems of prolonged apnoea.
870. von Dardel and S. Thesleff, 'Succinylcholine iodide as a muscle relaxant', Acta Chir. Scand., 1952,
103: 321-336.
88 F. Foldes, P. G. McNall and J. M. Borrego-Hinojosa, 'Succinylcholine: A new approach to muscular
relaxation in anesthesiology', Proc. Can. Anaesth. Soc., 1952, 38.
39S. H. S. Love, 'Prolonged apnoea following scoline', Anaesthesia, 1952, 7:113-114.
90 R. B. Gould, 'Succinylcholine chloride', [Correspondence], Br. med. J., 1952, i: 440.
91 J. K. Harper, 'Prolonged respiratory paralysis after succinylcholine', [Correspondence], ibid., 866.
92C L. Hewer, ibid., 971-972.
93 Whilst these reports were the first to be published, Lehmann received a communication from Davies in
1951 describing an apparently healthy soldier who had virtually no plasma pseudocholinesterase. H.
Lehmann, E. Silk and J. Liddell, 'Pseudo-cholinesterase', Br. med. Bull., 1961, 17: 230-233.
94It is difficult to overestimate the importance of suxamethonium in the development of phar-
macogenetics. The response to this drug was one of the two drug reactions based on genetically controlled
enzyme aberrations that provided the starting-point for studies in this area. (The other drug response was
the sensitivity of some individuals to the anti-malarial drug primaquine, shown to be the result of abnor-
malities in red cell glutathione metabolism.) See: A. G. Motulsky, 'Pharmacogenetics and ecogenetics: the
problem and its scope', in F. Vogel et al. (editors), Human genetic variation in response to medical and
environmental agents: pharmacogenetics and ecogenetics, (Human Genetics, supplement 1), Berlin,
Heidelberg, and New York, Springer, 1978, pp. 1-3; idem, 'Drug reactions, enzymes and biochemical
genetics', J. Am. med. Ass., 1957, 165: 835-837; F. Vogel, 'Moderne Probleme der Humangenetik',
Ergebn. inn. Med. Kinderheilk., 1959, 12: 52; A. G. Motulsky, 'History and current status of phar-
macogenetics', in Human genetics. Proc. 4th Internat. Congr. hum. Genet. (Paris, 1971), Amsterdam,
Excerpta Medica, 1972, pp. 381-390.
9"J. G. Bourne, H. 0. J. Collier and G. F. Somers, 'Succinylcholine - muscle relaxant of short action',
Lancet, 1952, i: 1225-1229.
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These papers also contained the first clues as to the mechanism of this phenomenon.
The enzymatic hydrolysis of suxamethonium had been known for some eleven years,
so it was thought that the plasma cholinesterase levels of suxamethonium-sensitive
patients should be compared with those of normal patients. It was found that "those
patients who recovered unusually slowly from succinylcholine had significantly lower
plasma-cholinesterase levels than did patients who recovered at the normal speed".96a
Significantly, the test used to measure the activity of plasma-cholinesterase involved
the evolution of carbon dioxide from a bicarbonate buffer by the products of ester
hydrolysis. It was assumed that the test accurately reflected the level of plasma-
cholinesterase present in the patient. It was known that certain conditions, such as
insecticide poisoning, malnutrition, and liver disease could depress levels of the
enzyme.97 At the time, this mechanism was not the only explanation put forward.
Acidaemia, synergism of suxamethonium with thiopentone, hyperventilation, and
overdosage of the drug were all suggested.9" There are many possible causes of
apnoea, however, although the evidence favouring the enzyme as the major determin-
ing factor was by far the most persuasive. Evans et al. concluded their paper with the
advice: "not to give succinylcholine to patients likely to have a low serum esterase
level, such as may be found in liver disease, severe anaemia and after poisoning with
anti-cholinesterase compounds"." The problem seemed solved, but then several cases
were reported where none of the above factors applied: "the patients appear to be in
good health, yet they show prolonged reaction to succinyldicholine and a correspond-
ingly low pseudocholinesterase level". 100101,102 In 1953, Forbat et al. came across one
such case and decided to investigate the patient's relatives.'03 They found that his
brother also had a low serum esterase level; and since he, too, was in all other respects
healthy, this pointed to a genetic factor in the aetiology ofsuxamethonium sensitivity.
Some three years later, one ofthe authors ofthe 1953 paper, Lehmann, published with
Ryan a study of the families of five unrelated suxamethonium-sensitive individuals
and suggested that the evidence pointed to "a recessive gene being responsible"''04
The next important contribution in unravelling this problem came from Kalow, a
"F. T. Evans, P. S. W. Gray, H. Lehmann and E. Silk, 'Sensitivity to succinylcholine in relation to
serum cholinesterase', ibid., 1229-1230.
9a Bourne etal., op. cit., note95 above, p. 1227.
97 It is interesting to note that Evans and his co-workers only became interested in suxamethonium
through plasma cholinesterase. Their work arose from a study ofthe useofplasma cholinesterase as aguide
to the functioning ofthe liver. (See note 79 above.)
98A. Forbat, H. Lehmann and E. Silk, 'Prolonged apnoea following injection of succinyldicholine',
Lancet, 1953, ii: 1067-1068.
" Evans etal., op. cit., note 96 above.
'°° Forbat etal., op. cit., note 98 above.
101 J. G. Bourne, 'Long action of suxamethonium (succinylcholine) chloride', Br. J. Anaesth., 1953, 25:
116-129.
102 See also note 93 above.
103 Op. cit., note 98 above. This step was to prove critical in the solution of the problem. Lehmann, in
retrospect, considers that interest in the various "haemoglobinopathies", which also have a genetic com-
ponent, was the reason why thisgrouptook this step.
104 H. Lehmann and E. Ryan, 'The familial incidence oflow pseudocholinesterase level', Lancet, 1956, ii:
124.
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pharmacologist who was to contribute much to the field of pharmacogenetics. In a
succession of papers in the late fifties, he and his co-workers demonstrated that the
presence of an abnormal enzyme rather than a lack of normal serum-cholinesterase
made certain otherwise healthy individuals sensitive to suxamethonium. 105,106,107,108
This conclusion differs from those made on the basis of earlier work. Because the
atypical form ofthe enzyme has less affinity for a substrate, e.g. suxamethonium, the
early observations had suggested less cholinesterase physically present in drug-
sensitive patients. In otherwise healthy patients, this was simply not the case - the
tests used were at fault because they reflected cholinesterase activity, rather than the
amount of enzyme, yet they were interpreted in terms of the latter.10'110'11' Such
abnormal enzymes had kinetic properties markedly different from normal -
suxamethonium and other substrates having a much lower avidity for the abnormal
enzyme. At typical concentrations of suxamethonium present during anaesthesia, the
abnormal enzyme has no detectable effect on the drug in contrast to the marked
hydrolytic effect of normal enzyme."2 Using a variety of methods, it has since been
shown that at least one of the two sites on the plasma-cholinesterase molecule which
normally bind a choline ester molecule is altered."3 Further work has suggested that
the "esteratic" site as well as the "anionic" site may be altered.""4"'11
The problem was made clearer by Kalow and his co-workers. A local anaesthetic
called Dibucaine (Nupercaine, Cinchocaine) was found to inhibit normal and atypical
forms of serum cholinesterase differentially. The gene responsible for the atypical
cholinesterase molecule is now designated E, , while the normal form is shown as El u.
Using this inhibitor, three distinct groups were characterized: (i) Individuals with an
enzyme that could be 80% inhibited. These were normal individuals carrying two
genes for the normal enzyme - homozygotes [E,uE,1. (ii) Suxamethonium-sensitive
individuals homozygous for the abnormal enzyme, which was 20% inhibited by
Dibucaine [E,a E10J (iii) Heterozygous individuals who carry one gene for normal
enzyme, and one for atypical enzyme. This group, which produced a mixture of
enzymes was intermediate, showing 52-69% inhibition. The syndrome of
suxamethonium sensitivity was thus clearly shown to have agenetic basis.
'05W. Kalow and K. Genest, 'A method for the detection of atypical forms of human serum
cholinesterase. Determination ofdibucaine numbers', Can. J. Biochem. Physiol., 1957, 35: 339-346.
106 W. Kalow and N. Staron, 'On the distribution and inheritance of atypical forms of human serum
cholinesterase as indicated by Dibucaine numbers', ibid., 1957, 35: 1305-1320.
107 R. 0. Davies, A. V. Marton and W. Kalow, 'The action of normal and atypical cholinesterase of
human serum upon a series ofesters', ibid., 1960,38: 545-551.
10* W. Kalow and R. 0. Davies, 'The activity ofvarious esterase inhibitors towards atypical human serum
cholinesterases', Biochem. Pharmac., 1959, 1: 183-192.
109 Evans etal., op. cit., note96 above.
10Forbat etal., op. cit., note 98 above.
"I H. Lehmann and P. H. Simmons, 'Sensitivity to suxamethonium apnoea in two brothers', Lancet,
1958,1: 981-982.
112 Davies et al., op. cit., note 107 above.
13 Kalow and Davies, op. cit., note 108 above.
114S. W. Clark, G. A. Glaubiger and B. N. La Du, 'Properties ofplasma cholinesterase variants', Ann.
N. Y. Acad. Sci., 1968,151: 710-722.
115 E. S. Vesell, 'Recent progress in pharmacogenetics',Adv. Pharm. Chemother., 1969,7: 1-52.
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Kalow's work showed that inheritance of the atypical enzyme was in a genetic
system where two non-dominant alleles - "normal" and "atypical" - operated [E, u
E,a. It is important to note that the substrate used in the Dibucaine experiments of
Kalow and co-workers was benzoylcholine, not suxamethonium, because it was much
easier technically to follow the former's hydrolysis reaction. Benzoylcholine could be
used because it too is a choline ester. Benzoic acid is, however, a monobasiccarboxylic
acid. This study, therefore, was based on the assumption that the hydrolysis of
benzoylcholine by plasmacholinesterase was a good kineticand mechanistic model for
the breakdown of suxamethonium."'1 The use of an inhibitor in the study of atypical
enzyme molecules was important, and, not surprisingly, this idea was subsequently
used by other workers. In the early 1960s, the inhibitor method was again applied,
using fluoride instead of dibucaine. Another allele on the same gene locus was
discovered, producing an enzyme which could hydrolyse suxamethonium at an inter-
mediate rate. 7""'8 This has been designated Elf A number of other inhibitors have
been used. These include urea, 119,120 sodium chloride,'2' n-butanol,'22 and
suxamethonium itself.'23 All of these have been used in systems using benzoylcholine
as substrate. Some ofthese inhibitors, notably sodium chloride'24 and n-butanol, have
been shown to inhibit some samples ofplasmacholinesterase in unusual ways and have
resulted in the postulation ofother alleles at this locus, which are not shown up well in
conventional Dibucaine tests.
More rarely, individuals who lack functional enzyme have been found.'25l126 Such
individuals are very susceptible to suxamethonium, and have to be ventilated for
several hours until the drug (which is not broken down enzymatically) is excreted.'27
'16A simple spectrophotometric method for following the hydrolysis of benzoylcholine, based on
measurement of absorbance at 240[ was developed early on. See W. Kalow and H. A. Lindsay, 'A com-
parison ofoptical and manometric methods for the assay ofhuman serum cholinesterase', Can. J. Biochem.
Physiol., 1955,33: 568-574.
A brief description ofthe problems with methods based on the hydrolysis of succinylcholine used before
1975 can be found in H. W. Goedde and D. P. Agarwal, 'Pseudocholinesterase Variation', in Vogel et al.,
op. cit., note 94 above, pp. 45-55.
117 H. Harris and M. Whittaker, 'Differential inhibition of human serum cholinesterase with fluoride:
recognition oftwo new phenotypes', Nature, Lond., 1961, 191: 496-498.
Idem, 'The serum cholinesterase variants. A study of 22 families selected via the "intermediate"
phenotype', Ann. hum. Genet., 1962,26: 59-72.
"9H. K. Hanel and J. Vilby Mogensen, 'Urea inhibition of human pseudocholinesterase', Br. J.
Anaesth., 1971, 43: 51-53.
120Idem, 'Theinhibition ofserum cholinesterase by urea', ibid., 1977, 49: 1251-1257.
121 M. Whittaker, 'The pseudocholinesterase variants. Differentiation by means of sodium chloride',
Acta. genet. statist. med., 1968, 18: 556-562.
122Idem, 'Differential inhibition of human serum cholinesterase with n-butylalcohol: recognition of new
phenotypes', ibid., 335-340.
123 J. King and D. Griffin, 'Differentiation of serum cholinesterase variants by succinyldicholine inhibi-
tion', Br. J. Anaesth., 1973, 45:450-454.
124 M. Whittaker, 'An additional pseudocholinesterase phenotype occurring in suxamethonium apnoea',
ibid., 1968,40: 579-582.
123 J. Liddell, H. Lehmann and E. Silk, 'A "silent" pseudocholinesterase gene', Nature, Lond., 1962, 193:
561-562.
126S. M. Hart and J. V. Mitchell, 'Suxamethonium in the absence of pseudocholinesterase', Br. J.
Anaesth., 1962,34: 207-209.
127S. E. Smith, 'Neuromuscular blocking drugs in man', in Zaimis, op. cit., note 66 above, pp. 593-660.
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Such individuals have what pharmacogeneticists call "silent" genes; homozygotes
occurring at the rate of 1 per 100,000 people. A survey of the literature on the silent
gene revealed that the majority of the world population described as having the silent
gene are Eskimos - partly due to inbreeding in an isolated Alaskan Eskimo
population.'28 The silent gene (designated E,) has subsequently been shown to be
heterogeneous. It was initially unclear whether it was the gene or its product, the
enzyme, that was "silent". It has since been shown that both these alternatives can be
found in nature: some individuals carrying the silent gene have very low enzyme
activity, about 2-8% of the normal level of cholinesterase activity, while there is
another group with no enzyme activity at all.'29-"3 It is thought that individuals
bearing the silent gene specifying the latter type of defect simply produce no enzyme
at all. The allele resulting in absence ofenzyme is now designated E, s while the allele
characterized by low enzyme activity is designated E,T A third variant within the
silent group, E,R, also with less than 10% of the normal activity was recently found in
an Alaskan Eskimo.'34 Other silent gene variants may yet be discovered.
Individuals with abnormally high cholinesterase activity have also been reported.
There are two types. One, present in the British population, results in an average level
of serum cholinesterase activity some 30% above normal, a margin too slight to have
clinical significance.'" Individuals with this variant possess an extra serum
cholinesterase component, designated C5. The second version, discovered in
Cynthiana, Kentucky,136 and therefore now designated ECynth"ana confers resist-
ance to suxamethonium. Individuals with this allele were shown to hydrolyse the
drug much faster - the plasma enzyme activity being three times the normal. This
variant has both a qualitative and a quantitative dimension: a biochemically different
cholinesterase molecule is being produced, as in the examples described above, but
also there is an elevated amount of enzyme present in the serum of individuals with
this allele.
128 B. B. Gutsche, E. M. Scott and R. C. Wright, 'Hereditary deficiency of pseudocholinesterase in
Eskimos', Nature, Lond., 1967, 215: 322-323.
129 H. W. Goedde, D. Gehring and R. Hoffman, 'On the problem of a "silent gene" in the polymorphism
ofpseudocholinesterases', Biochim. Biophys. Acta, 1965, 107: 391-393.
130 H. W. Goedde and K. Altland, 'Suxamethonium sensitivity', Ann. N.Y. Acad. Sci., 1971, 179:
695-703
131 W. E. Hodgkin, E. R. Giblett, H. Levine, W. Bauer and A. G. Motulsky, 'Complete
pseudocholinesterase deficiency: genetic and immunologic characterization', J. clin. Inv., 1965, 44:
486-493.
132 E. M. Scott, 'Inheritance of two types of deficiency of human serum cholinesterase', Ann. hum.
Genet., 1973, 37: 139-143. See also, Gutsche, op. cit., note 128 above.
133 H. W. Goedde and K. Altland, 'Evidence for the different "silent genes" in the human serum
pseudocholinesterase polymorphism', Ann. N.Y. Acad. Sci., 1968, 151: 540-544.
134 E. M. Scott and R. C. Wright, 'A third type of serum cholinesterase deficiency in Eskimos', Am. J.
hum. Genet., 1976, 28: 253-256.
133 H. Harris, D. A. Hopkinson, E. B. Robson and M. Whittaker, 'Genetical Studies on a new variant of
serum cholinesterase detected by electrophoresis.', Ann. hum. Genet., 1963, 26: 359-382.
136 H. W. Neitlich, 'Increased plasma cholinesterase activity and succinylcholine resistance: a genetic
variant',J. clin. Invest., 1966,45: 380-387.
137 A. Yoshida and A. G. Motulsky, 'A pseudocholinesterase variant (E Cynthiana) associated with
elevated plasma enzyme activity', Am. J. hum. Genet., 1969, 21: 486-498.
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The concept of quantitative variation in plasmacholinesterase levels has only
recently been considered to have a genetic basis. This is probably for two reasons:
first, the idea that abnormal response to suxamethonium was solely a function ofthe
amount (cf. the activity) ofplasmacholinesterase was, as we have seen, an idea which
confused much of the early thinking about this problem. Second, a number of well-
documented causes of reduced enzyme levels (e.g., liver disease) exist.138 It is clearly
difficult to distinguish between these conditions where the synthesis ofnormal enzyme
is depressed because of disease or malnutrition, and genetic determinants causing
reduced synthesis of normal enzyme. Nonetheless, two quantitative variants have
recently been described. One of these, Eli causes a 65-70% reduction in circulating
normal cholinesterase molecules,'39"140 while the other, Elk, causes a 33%
reduction.""41,42
As we have noted, the substrate used in nearly all of the studies described above
was benzoylcholine, not suxamethonium. This further illustrates that the way in which
the problem was approached has necessarily limited the usefulness ofthe answers. The
use of benzoylcholine in tests on sera from affected patients provided no information
on the ability ofthese sera to hydrolyse suxamethonium. It is clearly desirable to use
suxamethonium itself as a substrate in these assays. This innovation really had to
await the development in 1975 of a convenient method for following the hydrolysis
reaction,"13"" I whereby samples of sera previously classified as normal, which came
from patients with a history of prolonged apnoea, were reexamined with
suxamethonium as substrate and Dibucaine as inhibitor. This has resulted in the
discovery of a new variant with altered properties toward succinyldicholine but not
toward benzoylcholine. The new variant has been provisionally designated ElSu1
although further investigation is necessary. This technique may reveal several new
variants ofplasmacholinesterase."15 The variants ofplasmacholinesterase are listed in
Table I:
" A list of these conditions may be found in M. Whittaker, 'Plasma cholinesterase variants and the
anaesthetist', Anaesthesia, 1980, 35: 174-197. This is an excellent recent review ofthe clinical aspects ofthis
topic.
139 P. J. Garry, A. A. Dietz, T. Lubrano, P. C. Ford, K. James and H. M. Rubinstein, 'New allele at
cholinesterase locus 1',J. Med. Genet., 1976, 13: 38-42.
140 H. M. Rubinstein, A. A. Dietz, T. Lubrano and P. J. Garry, 'E,J, a quantitative variant at
cholinesterase locus 1: immunological evidence', ibid., 1976, 13: 43-45.
141 H. M. Rubinstein, A. A. Dietz and T. Lubrano, 'E, K another quantitative variant at cholinesterase
locus ', ibid., 1978, 15: 27-29.
142The E,k variant was so named in recognition of the work of Kalow in clarifying the recognition and
inheritance ofthe "atypical" allele.
143 Methods for following the hydrolysis of suxamethonium were available before 1975, but these were
time-consuming and difficult.
144 D. P. Agarwal, S. Schwenkenbecher, L. M. Srivastava, H. W. Goedde, 'Spektrophotometrische
Bestimmungsmethode fUr serumcholinesterase (EC 3.1.1.8) - varianten mit succinylbischolin als substrat,
Z. klin. Chem. klin. Biochem., 1975, 13:133-135.
145 Goedde and Agarwal, op. cit., note 116 above.
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TABLE I
GENETICALLY DETERMINED VARIANTS OF
PLASMACHOLINESTERASE [EC 3.1.1.8]
Name Symbol Hydrolysis Authors and Date ofDiscovery
ratefor
Suxamethonium
Normal Elu 100%
Atypical Ela Reduced Lehmann and Ryan 1956 (104)
[Dibucaine-Resistant] Kalow and Genest 1957 (105)
Fluoride-Resistant Elf Intermediate Harris and Whittaker 1961 (117, 118)
'Silent'
No enzyme Els Nil Liddell, Lehmann and Silk 1962(125)
V. Low Activity ElT 2-8% Gutsche etal. 1967(128)
V. Low Activity ElR < 10% Scott and Wright 1976(134)
'C5' E2+ Increased slightly Harris etal. 1963 (135)
Cynthiana ECynthiana Greatly Increased Neitlich 1966 (136)
EIJ Reduced Garry etal. 1976(139)
Quantitative variants ~ Ek Rubinstein etal. 1976(140)
Elk Reduced Rubinstein etat. 1978 (141)
E,su Reduced Goedde and Agarwal 1978 (145)
Note: The hydrolysis rate for suxamethonium observed clinically is altered for E,', ECyntliapa E,i and E,k
predominantly because these alleles cause a change in the amount rather than the activity of enzyme
produced.
The story ofsuxamethonium apnoea can be continued up to the present day. It was
recognized quite early in the analysis ofthis problem that the prolonged response to
suxamethonium was associated with a low level of pseudocholinesterase activity. It
was suggested that rather than ventilate until the patient recovered through removal of
the drug by excretion, it would be desirable to treat the apnoea by injection of a con-
centrated preparation of pseudocholinesterase. Such a preparation became available
from the Cutter Company of California. It was injected successfully when an
individual was actually experiencing prolonged apnoea following injection of
suxamethonium.1""4'7 However, it was not possible to continue this work, because
some of the concentrated preparations proved antigenic, and some may have been
contaminated with virus. In 1968, a suitable enzyme preparation became available in
46J. Calvert, H. Lehmann, E. Silk and W. K. Slack, 'Prolonged apnoea after suxamethonium - a case
study ofpseudocholinesterase', Lancet, 1954,11: 354-356.
147 Lehmann and Simmons, op. cit., note 111 above.
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Germany.'48 This was tested and recommended for general use in suxamethonium
apnoea. It is commonly used in Germany today."49 British interest in this problem is
now reviving, and the use of enzyme preparations in the treatment of prolonged
apnoea may yet become established clinical practice in the U.K.'5O
More work needs to be done on apnoea and its causation - defective enzymes are
not the entire story. In a study by Thompson and Whittaker,"' it was shown that one-
third of all the patients in their sample group who had experienced prolonged apnoea
were of normal genotype in relation to this enzyme, and had normal cholinesterase
activity! It is likely that at least some of these individuals possess variant forms of
plasmacholinesterase as yet undiscovered.
The importance of suxamethonium to pharmacogenetics was acknowledged by
Kalow, when concluding the First International Conference on Pharmacogenetics in
1967: "some of the topics like ... prolonged action of succinylcholine and slow
inactivation ofisoniazid have been godfathers to the field ofpharmacogenetics".'"2
7. OTHER EFFECTS OF SUXAMETHONIUM
I have concentrated on one major side-effect seen with suxamethonium because of
its considerable importance in influencing ideas in the fields of genetics and phar-
macology as well as in areas of clinical interest. However, apnoea is not the only
problem with suxamethonium. In the current edition of Martindale,"' some thirteen
different effects are listed. Some of them are due to the cholinomimetic properties of
the drug, e.g., bradycardia.
As a result of depolarizing the end-plate, suxamethonium causes release of
potassium from inside the muscle cells into theextracellular space, and thence into the
blood plasma. Fortunately, in only a small group of patients - those who have been
severely burned, and those who have neurological injuriesl54-has the problem become
serious. The risk is that the plasma level ofpotassium will reach a value high enough
to cause cardiac arrest.
In addition, suxamethonium has contributed to legal, as well as medical, history. It
was used for a murder, and it is still controversial whether the drug or its breakdown
products can bedetected in the body ofavictim.'55
148 H. W. Goedde, K. Altland and W. Schloot, 'Therapy ofprolonged apnoea after suxamethonium with
purified pseudocholinesterase: new data on kinetics of the hydrolysis of succinyldicholine and
succinylmonocholonine and further data on N-acetyltransferase polymorphism', Ann. N. Y. Acad. Sci.,
1968,151:742-752.
149GGoeddeand Altland, op. cit., note 130 above.
150H. Lehmann, personal communication, 1979.
151 J. C. Thompson and M. Whittaker, 'A study ofthe pseudocholinesterase in 78 cases ofapnoea follow-
ingsuxamethonium', Actagenet. Statist. med., 1966, 16: 209-222.
152 W. Kalow, 'Concluding remarks', Ann. N.Y. Acad. Sci., 1968, 151: 1001.
"I W. Martindale (editor), The extrapharmacopoeia, 27th ed., London, Pharmaceutical Press, 1977.
1"4 Cf. a recent report indicating that suxamethonium can precipitate ventricular arrhythmias in patients
with polyneuropathy: R. J. Fergusson, D. J. Wright, R. F. Willey, G. K. Compton and I. W. B. Grant,
'Lesson ofthe week: suxamethonium is dangerous in polyneuropathy', Br. med. J., 1981, i: 298-299.
"I In April 1967, a Florida anaesthetist was convicted of killing his wife with succinylcholine chloride.
Respiratory paralysis would occur with a sufficient dose ofthe drug, and in the absence ofartificial ventila-
tion, this would, ofcourse, result in death. In retrospect, the crime seems very elegant, for the hydrolysis of
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Finally, mention must be made of suxamethonium as a pharmacological tool.
Curiously, whilst this drug was designed as a synthetic curare compound, its phar-
macology is surprisingly different."'6 Unlike curare, it depolarizes the postsynaptic
membrane and causes muscle fasciculations (and thus, in some patients, post-
operative pain). Suxamethonium, and decamethonium, are as important in the
development of new ideas within pure pharmacology as in clinical work. Research on
the detailed properties ofcholinergic receptors and their "desensitization" properties
goes on to thisday.'15718159
The above account has shown the history of suxamethonium to be surprisingly
complex for a drug that many consider to have been developed by logical considera-
tion of features of the d-tubocurarine molecule. There can be little doubt that
suxamethonium research made a major contribution to the development of phar-
macogenetics in the 1950s. Suxamethonium is now almost a field of its own. Many
hundreds of papers have been published about the drug, and since 1957, it has had its
own subject heading in Index Medicus. It is likely that it will remain in clinical use for
some years to come, and that further research into its mode ofaction and thegenetics
ofplasmacholinesterasewill be undertaken.
SUMMARY
In comparison with some drugs, suxamethonium appears to have had a simple
origin. It was developed from the methonium compounds in the late 1940s. These
compounds are one family in a group ofdrugs based on structural features of the d-
tubocurarine molecule. Whilst the neuromuscular blocking properties, and thus the
potential clinical usefulness, of suxamethonium were first demonstrated by Bovet in
1949, a number ofearlier workers had made and tested the drug. One ofthese groups
had worked some forty years before Bovet's success. For a variety of reasons, they
failed to show its majorphysiological action.
the drug, described by Glick, (op. cit., note 61 above), results in succinate and choline - many grams of
which arealready present in the body. Functionally, the drug seems to disappear without trace.
It is still a matter ofdebate as to whether it is possible to detect raised levels ofthe hydrolysis products of
suxamethonium, when the dose needed to block respiration is low, and there is likely to be some variation in
the levels ofcholine and succinate present physiologically. In the early 1960s it was thought impossible to
detect this drug in the human body. New tests were stimulated by, and devised for, the trial of the
anaesthetist. It is thevalidity ofthese tests that is currently under attack. Alex Gringauz, Drugs - how they
act and why, Saint Louis, C. V. Mosby, 1978. (I am indebted to Mr. P. J. Turpin for this reference.) A.
Gringauz, personal communication, 1979. Southern Reporter, 2nd series, vol. 223, St. Paul, Minn., West
Publishing, 1969, pp. 68-76. [Update], 'Coppolino: hopes for vindication', Newsweek Mag., 7 May 1979.
156 E. J. Zaimis, 'The neuromuscularjunction: areas ofuncertainty', in Zaimis, op. cit., note 66 above, pp.
1-21.
157 It has recently been shown that decamethonium acts by opening, and then blocking ion channels. See
P. R. Adams and B. Sakmann, 'Decamethonium both opens and blocks endplate channels', Proc. Nat.
Acad. Sci. (U.S.A.), 1978, 75: 2994-2998.
In view of the similar pharmacological properties of suxamethonium, it seems likely that it too acts by
ion channel blockade. However, this remains to be conclusivelydemonstrated.
158 A good guide to the electrophysiological analysis ofthe action ofneuromuscular blocking agents can
be found in Colquhoun, op. cit., note 67 above. See also, P. R. Adams, 'Molecular aspects of synaptic
transmission', Trends Neurosci., 1987, 1: 141-143.
159D. Wray, 'Frequency ofopening ofchannels by depolarizingdrugs',J. Physiol., 1978, 284: 149-150.
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The history of suxamethonium after its initial adoption for clinical use is
particularly interesting. One side-effect - prolonged respiratory depression - proved
to be a very complex problem. Its solution made an invaluable contribution to
pharmacogenetics - the understanding of the genetic control of the response of an
individual to drugs. The way in which this problem was solved illustrates how the use
ofcertain methods can determine the nature and usefulness ofthe results obtained.
Suxamethonium has also contributed to the understanding of fundamental
mechanisms at the neuromuscular junction. Paradoxically, it is a depolarizing drug,
with a mode of action different from that of d-tubocurarine despite their common
structural features.
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